We are upgrading the repository! A content freeze is in effect until December 6th, 2024 - no new submissions will be accepted; however, all content already published will remain publicly available. Please reach out to repository@u.library.arizona.edu with your questions, or if you are a UA affiliate who needs to make content available soon. Note that any new user accounts created after September 22, 2024 will need to be recreated by the user in November after our migration is completed.
Early and late preterm birth rates in participants adherent to randomly assigned high dose docosahexaenoic acid (DHA) supplementation in pregnancy
Name:
1-s2.0-S0261561423000110-main.pdf
Size:
1020.Kb
Format:
PDF
Description:
Final Published Version
Author
Carlson, S.E.Gajewski, B.J.
Valentine, C.J.
Sands, S.A.
Brown, A.R.
Kerling, E.H.
Crawford, S.A.
Buhimschi, C.S.
Weiner, C.P.
Cackovic, M.
DeFranco, E.A.
Mudaranthakam, D.P.
Rogers, L.K.
Affiliation
Department of Pediatrics, University of ArizonaIssue Date
2023-02
Metadata
Show full item recordPublisher
Churchill LivingstoneCitation
Carlson, S. E., Gajewski, B. J., Valentine, C. J., Sands, S. A., Brown, A. R., Kerling, E. H., ... & Rogers, L. K. (2023). Early and late preterm birth rates in participants adherent to randomly assigned high dose docosahexaenoic acid (DHA) supplementation in pregnancy. Clinical Nutrition, 42(2), 235-243.Journal
Clinical NutritionRights
© 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/).Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Background: Intention-to-treat analyses do not address adherence. Per protocol analyses treat nonadherence as a protocol deviation and assess if the intervention is effective if followed. Objective: To determine the rate of early preterm birth (EPTB, <34 weeks gestation) and preterm birth (PTB, <37 weeks gestation) in participants who adhered to a randomly assigned docosahexaenoic acid (DHA) dose of 1000 mg/day. Study design: Eleven hundred women with a singleton pregnancy were enrolled before 20-weeks’ gestation, provided a capsule with 200 mg/day DHA and randomly assigned to two additional capsules containing a placebo or 800 mg of DHA. In the Bayesian Adaptive Design, new randomization schedules were determined at prespecified intervals. In each randomization, the group with the most EPTB was assigned fewer participants than the other group. Adherence was defined a priori as a postpartum red blood cell phospholipid DHA (RBC-PL-DHA) ≥5.5%.and post hoc as ≥8.0% RBC-PL-DHA, the latter after examination of postpartum RBC-PL-DHA. Bayesian mixture models were fitted for gestational age and dichotomized for EPTB and PTB as a function of baseline RBC-PL-DHA and dose-adherence. Bayesian hierarchical models were also fitted for EPTB by dose adherence and quartiles of baseline RBC-PL-DHA. Results: Adherence to the high dose using both RBC-PL-DHA cut points resulted in less EPTB compared to 200 mg [Bayesian posterior probability (pp) = 0.93 and 0.92, respectively]. For participants in the two lowest quartiles of baseline DHA status, adherence to the higher dose resulted in lower EPTB (≥5.5% RBC-PL-DHA, quartiles 1 and 2, pp = 0.95 and 0.96; ≥8% RBC-PL-DHA, quartiles 1 and 2, pp = 0.94 and 0.95). Using the Bayesian model, EPTB was reduced by 65%, from 3.45% to 1.2%, using both cut points. Adherence also reduced PTB before 35, 36 and 37 weeks using both cut points (pp ≥ 0.95). In general, performance of the nonadherent subgroup mirrored that of participants assigned to 200 mg. Conclusion: Adherence to high dose DHA reduced EPTB and PTB. The largest effect of adherence on reducing EPTB was observed in women with low baseline DHA levels. ClinicalTrials.gov (NCT02626299). © 2023 The Author(s)Note
Open access articleISSN
0261-5614PubMed ID
36680919Version
Final Published Versionae974a485f413a2113503eed53cd6c53
10.1016/j.clnu.2023.01.009
Scopus Count
Collections
Except where otherwise noted, this item's license is described as © 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Related articles
- Assessment of DHA on reducing early preterm birth: the ADORE randomized controlled trial protocol.
- Authors: Carlson SE, Gajewski BJ, Valentine CJ, Rogers LK, Weiner CP, DeFranco EA, Buhimschi CS
- Issue date: 2017 Feb 13
- DHA supplementation for early preterm birth prevention: An application of Bayesian finite mixture models to adaptive clinical trial design optimization.
- Authors: Shi X, Wick JA, Christifano DN, Carlson SE, Brown AR, Mudaranthakam DP, Gajewski BJ
- Issue date: 2024 Sep
- Docosahexaenoic acid (DHA) intake estimated from a 7-question survey identifies pregnancies most likely to benefit from high-dose DHA supplementation.
- Authors: Christifano DN, Crawford SA, Lee G, Brown AR, Camargo JT, Kerling EH, Gajewski BJ, Valentine CJ, Gustafson KM, DeFranco EA, Carlson SE
- Issue date: 2023 Feb
- DHA, nutrient intake, and maternal characteristics as predictors of pregnancy outcomes in a randomised clinical trial of DHA supplementation.
- Authors: Wang Y, Gajewski BJ, Valentine CJ, Crawford SA, Brown AR, Mudaranthakam DP, Camargo JT, Carlson SE
- Issue date: 2023 Nov
- Dose-response relationship between docosahexaenoic acid (DHA) intake and lower rates of early preterm birth, low birth weight and very low birth weight.
- Authors: Carlson SE, Gajewski BJ, Alhayek S, Colombo J, Kerling EH, Gustafson KM
- Issue date: 2018 Nov